About

Eltrombopag is an orally bioavailable, small-molecule thrombopoietin receptor agonist that specifically stimulates the proliferation and differentiation of megakaryocytes from bone marrow stem cells. This targeted action leads to a significant increase in platelet production, effectively elevating and maintaining platelet counts in patients suffering from various thrombocytopenic conditions. By binding to the transmembrane domain of the thrombopoietin receptor (TPO-R) on megakaryocytes, eltrombopag initiates intracellular signaling cascades that promote cell growth and differentiation, thereby reducing the risk of bleeding episodes. Its mechanism is distinct from endogenous thrombopoietin, offering a crucial therapeutic option for individuals who have not responded adequately to other conventional treatments, such as corticosteroids or splenectomy. It is particularly valuable in chronic immune thrombocytopenia, severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C, providing a non-immunosuppressive approach to managing low platelet counts and improving patient quality of life.

Uses

Chronic immune (idiopathic) thrombocytopenia (ITP)
Severe aplastic anemia (SAA)
Thrombocytopenia in chronic hepatitis C
Refractory thrombocytopenia

Directions For Use

Take orally once daily on an empty stomach, at least one hour before or two hours after meals, or as directed by your physician.

Benefits

Increases platelet count
Reduces risk of bleeding
Oral administration
Improves quality of life
Effective in refractory cases
Supports surgical procedures

Side Effects

Nausea
Diarrhea
Abdominal pain
Fatigue
Headache
Muscle pain
Cough
Fever
Increased liver enzymes
Thromboembolic events
Cataracts
Bone marrow changes

Safety Measures

Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver-related side effects or interact with the medication.
Pregnancy - Not recommended during pregnancy unless clearly necessary, as it may cause fetal harm. Consult a doctor.
Breastfeeding - It is unknown if Eltrombopag is excreted in human milk. Breastfeeding is generally not recommended due to potential risks to the infant.
Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary, and liver function should be monitored closely.
Kidney - Generally considered safe in patients with renal impairment, but caution is advised, and monitoring may be appropriate.
Lung - No specific contraindications related to lung conditions, but general patient health should be considered.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.

Shipping & Location